These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 35451727

  • 1. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP, Hoskin TL, Day CN, Sanders SB, Boughey JC.
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [Abstract] [Full Text] [Related]

  • 2. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A, Riedel F, Feißt M, Köpke M, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Heil J.
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [Abstract] [Full Text] [Related]

  • 3. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
    Davis J, Boughey JC, Hoskin TL, Day CN, Cheville JC, Piltin MA, Hieken TJ.
    Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043
    [Abstract] [Full Text] [Related]

  • 4. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J.
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [Abstract] [Full Text] [Related]

  • 5. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM, Spronk PER, Vugts G, van Dalen T, Peeters MTFDV, Rots ML, Kuijer A, Nieuwenhuijzen GAP, Schipper RJ.
    Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
    [Abstract] [Full Text] [Related]

  • 6. Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
    van Steenhoven JEC, van Maaren MC, Verreck EEF, Schipper RJ, Nieuwenhuijzen GAP, Kuijer A, Siesling S, van Dalen T.
    Int J Cancer; 2023 Apr 01; 152(7):1378-1387. PubMed ID: 36522834
    [Abstract] [Full Text] [Related]

  • 7. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.
    Eur J Surg Oncol; 2017 Apr 01; 43(4):672-679. PubMed ID: 28139362
    [Abstract] [Full Text] [Related]

  • 8. Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy.
    Vane MLG, Hunter-Squires J, Kim S, Smidt ML, Giuliano AE.
    Ann Surg Oncol; 2021 May 01; 28(5):2522-2528. PubMed ID: 33586070
    [Abstract] [Full Text] [Related]

  • 9. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Prathibha S, White M, Kolbow M, Hui JYC, Brauer D, Ankeny J, Jensen EH, LaRocca CJ, Marmor S, Tuttle TM.
    Breast Cancer Res Treat; 2024 May 01; 205(1):127-133. PubMed ID: 38281296
    [Abstract] [Full Text] [Related]

  • 10. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
    Williams AD, Ruth K, Shaikh SS, Vasigh M, Pronovost MT, Aggon AA, Porpiglia AS, Bleicher RJ.
    Cancer; 2024 Apr 01; 130(7):1052-1060. PubMed ID: 38018862
    [Abstract] [Full Text] [Related]

  • 11. Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes.
    Kantor O, Means J, Grossmith S, Dey T, Bellon JR, Mittendorf EA, King TA.
    Ann Surg Oncol; 2022 Feb 01; 29(2):972-980. PubMed ID: 34467507
    [Abstract] [Full Text] [Related]

  • 12. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F, Heil J, Feisst M, Moderow M, von Au A, Domschke C, Michel L, Schaefgen B, Golatta M, Hennigs A.
    Breast Cancer Res Treat; 2020 Nov 01; 184(2):627-636. PubMed ID: 32816190
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
    Tadros AB, Moo TA, Stempel M, Zabor EC, Khan AJ, Morrow M.
    Breast Cancer Res Treat; 2020 Feb 01; 180(1):197-205. PubMed ID: 31938938
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.